Compare Cassava Sciences Inc (FLNA) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs 22nd Century Group Inc — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while 22nd Century Group Inc trades at $4.33 (market cap $1.52M). The key difference: Cassava Sciences Inc is far larger — about 35× 22nd Century Group Inc's market cap. Which is the better fit depends on your goals.
| FLNA | XXII | |
|---|---|---|
Market Cap | $53.14M | $1.52M |
Sector | Health | Technology |
52-Week High | $4.64 | $1.47K |
52-Week Low | $1.09 | $3.90 |
Enterprise Value | -$33.43M | -$6.71M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
22nd Century Group (XXII) trades at $4.33, up 3.34% on the day, following a recent 20:1 reverse stock split. The stock shows a bearish technical signal with support at $4 and resistance at $5. Fundamentally, the company continues to operate at a loss with negative gross and net profit margins, though revenue reached $7.05M in 2025. Recent news highlights aggressive expansion of its VLN reduced-nicotine cigarette brand into California and New York markets.
The outlook remains speculative with significant execution risk. While analyst consensus is strongly bullish (75% buy ratings), the company must demonstrate a path to profitability through its VLN product expansion. Key risks include persistent cash burn, competitive tobacco market pressures, and regulatory uncertainty. The stock represents a high-risk, high-potential turnaround play dependent on commercial success of its reduced-nicotine platform.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
